Yuting Wu

Yuting Wu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HFHuijie Fan
Huijie Fan
ZXZe-Ping Xie
Ze-Ping Xie
ZLZi-Wen Lu
Zi-Wen Lu
ZTZhang-Bin Tan
Zhang-Bin Tan
YBYi-Ming Bi
Yi-Ming Bi
YZYingchun Zhou
Yingchun Zhou

1 August 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HFHuijie Fan
Huijie Fan
XZXiaoshan Zhao
Xiaoshan Zhao
ZTZhang-Bin Tan
Zhang-Bin Tan
BLBin Liu
Bin Liu
HXHong-Lin Xu
Hong-Lin Xu
YZYingchun Zhou
Yingchun Zhou

1 March 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZTZhang-Bin Tan
Zhang-Bin Tan
HFHuijie Fan
Huijie Fan
YWYuting Wu
Yuting Wu
LXLing-Peng Xie
Ling-Peng Xie
YBYi-Ming Bi
Yi-Ming Bi
YZYingchun Zhou
Yingchun Zhou

7 June 2025 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DWDong Wang
Dong Wang
LLLei Li
Lei Li
FZFeng Zhang
Feng Zhang
QLQian Liu
Qian Liu
WWWen-Long Wang
Wen-Long Wang
PBPeili Bu
Peili Bu

26 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
FZFeng Zhang
Feng Zhang
LLLei Li
Lei Li
QLQian Liu
Qian Liu
WWWen-Long Wang
Wen-Long Wang
ZWZhi-Xin Wang
Zhi-Xin Wang
YWYuting Wu
Yuting Wu
Background: Tanshinone I (Tan I) has diverse cardioprotective effects, including improving post-myocardial infarction (MI) ventricular remodeling. Ventricular remodeling can be improved by inhibiting endothelial cell (EC) ferroptosis to promote post-MI angiogenesis, but how Tan I does this remains unclear. Thus, we investigated how EC ferroptosis mediates post-MI angiogenesis and Tan I's role in this process.Methods: In vivo experiments: A mouse model of MI was established to evaluate cardiac function, myocardial injury, collagen deposition, and EC ferroptosis. CD31 expression was measured to assess angiogenesis, and western blot analysis was used to detect ALDH2 signaling-related proteins (ALDH2, xCT, GPX4). In vitro experiments: Ferroptotic human umbilical vein endothelial cells (HUVECs) induced by erastin were treated with Tan I to assess ferroptosis, cell proliferation, migration, and tubular network formation. Western blot analysis was used to detect ALDH2 signaling-related proteins. Additionally, the role of Tan I was further verified by using the ferroptosis inhibitor ferrostatin-1, the ALDH2 agonist Alda-1, or the ALDH2 inhibitor daidzein in vitro and in vivo models, respectively.Results: We found that Tan I improved post-infarction cardiac function and myocardial injury, inhibited post-infarction collagen deposition and EC ferroptosis, and promoted CD31 expression in vivo by activating ALDH2 and promoting ALDH2 signaling-related protein levels. Additionally, Tan I inhibited ferroptosis, promoted proliferation and migration, and enhanced tubular network formation in HUVECs in vitro by activating ALDH2 and promoting ALDH2 signaling-related protein levels.Conclusion: Tan I may improve ventricular remodeling by activating ALDH2 signaling, inhibiting EC ferroptosis, and promoting angiogenesis.

27 October 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
XXXinyu Xue
Xinyu Xue
HZHui Zhang
Hui Zhang
YCYunlong Cao
Yunlong Cao
ZWZhixin Wang
Zhixin Wang
QSQiuyu Song
Qiuyu Song
QLQian Liu
Qian Liu
Pulmonary arterial hypertension (PAH) remains a high-mortality vasculopathy for which no current therapy reverses established vascular remodeling. Stem cell-based and cell-free extracellular vesicle (EV) therapies are promising disease-modifying strategies, yet prior PAH bibliometric studies have not treated this stem-cell-to-cell-free arc as a dedicated, continuous research front. We analyzed 891 articles and reviews (1 January 2006 to 15 March 2026) from the Web of Science Core Collection and PubMed using CiteSpace, VOSviewer, R bibliometrix, and logistic growth modeling. Annual output grew steeply to 2012 and has since held a level of about 50 publications a year, with no trend over 2013–2025 (slope +0.44 publications per year, 95% CI −0.49 to +1.37). Cumulative output followed an S-shaped logistic trajectory ( R 2 = 0.860), but the fitted saturation capacity is not identified by these data and is reported as indicative only. Co-citation, clustering and keyword-burst analyses support a descriptive three-phase framework of the field's development: endothelial progenitor cell-based replacement (2006–2012), the expansion of mesenchymal stromal cell (MSC) research (2013–2021), and a cell-free EV/exosome phase (2022–2026) marked by the strongest keyword burst in the dataset (extracellular vesicles, 12.55) and by active bursts for exosomes (6.80) and endothelial dysfunction (6.57). The United States (273) and China (223) led output, with Stanford University, Stewart D.J., and Humbert M. anchoring the knowledge network. Manufacturing standardization, targeting efficiency, and large-scale clinical evidence remain unresolved, and no phase III trial has been completed for any stem cell- or EV-based product. To our knowledge, these findings provide the first quantitative mapping of this stem-cell-to-cell-free transition in PAH, and identify the directions in which research attention is concentrating.